209 related articles for article (PubMed ID: 15048586)
1. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.
Sugarbaker PH; Stuart OA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):151-5. PubMed ID: 17091250
[TBL] [Abstract][Full Text] [Related]
3. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
4. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
Jacquet P; Averbach A; Stuart OA; Chang D; Sugarbaker PH
Cancer Chemother Pharmacol; 1998; 41(2):147-54. PubMed ID: 9443628
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
8. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH
Oncology; 1998; 55(2):130-8. PubMed ID: 9499187
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
[TBL] [Abstract][Full Text] [Related]
11. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
12. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
Zeamari S; Floot B; van der Vange N; Stewart FA
Anticancer Res; 2003; 23(2B):1643-8. PubMed ID: 12820435
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intraperitoneal gemcitabine in a rat model.
Pestieau SR; Stuart OA; Chang D; Jacquet P; Sugarbaker PH
Tumori; 1998; 84(6):706-11. PubMed ID: 10080682
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
[TBL] [Abstract][Full Text] [Related]
17. Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea.
Esquivel J
Cancer J; 2009; 15(3):249-54. PubMed ID: 19556912
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
19. Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.
Sørensen O; Andersen AM; Kristian A; Giercksky KE; Flatmark K
J Surg Oncol; 2014 May; 109(6):521-6. PubMed ID: 24347444
[TBL] [Abstract][Full Text] [Related]
20. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
Vahrmeijer AL; van Dierendonck JH; Keizer HJ; Beijnen JH; Tollenaar RA; Pijl ME; Marinelli A; Kuppen PJ; van Bockel JH; Mulder GJ; van de Velde CJ
Br J Cancer; 2000 May; 82(9):1539-46. PubMed ID: 10789721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]